Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ивабрадин дополняет клиническую эффективность чрескожного коронарного вмешательства у больных ишемической болезнью сердца со стабильной стенокардией
Аронов Д.М., Бубнова М.Г. Ивабрадин дополняет клиническую эффективность чрескожного коронарного вмешательства у больных ишемической болезнью сердца со стабильной стенокардией. КардиоСоматика. 2017; 8 (2): 35–43.
________________________________________________
Aronov D.M., Bubnova M.G. Ivabradinum supplements the clinical efficacy of percutaneous coronary intervention in patients with coronary heart disease with stable angina. Cardiosomatics. 2017; 8 (2): 35–43.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обзор посвящен роли ивабрадина в процедуре чрескожного коронарного вмешательства (ЧКВ) у больных ишемической болезнью сердца со стабильной стенокардией. Приводятся данные о том, что реперфузия миокарда с помощью ЧКВ даже в сочетании с современной медикаментозной терапией не оказывает полного клинического эффекта. Авторы обосновывают возможность дополнения клинического эффекта ЧКВ у таких больных назначением им ивабрадина. Препарат снижает частоту сердечных сокращений в большей степени, чем при медикаментозной терапии без него.
Ключевые слова: чрескожное коронарное вмешательство, реперфузия миокарда, стабильная стенокардия, функциональный класс стенокардии, качество жизни.
Ключевые слова: чрескожное коронарное вмешательство, реперфузия миокарда, стабильная стенокардия, функциональный класс стенокардии, качество жизни.
________________________________________________
The review is devoted to the role of ivabradinum in the procedure of percutaneous coronary intervention (PCI) in patients with ischemic heart disease with stable angina. It is reported that reperfusion of the myocardium with PCI, even in combination with modern drug therapy, does not have a complete clinical effect. The authors substantiate the possibility of completing the clinical effect of PCI in such patients by prescribing ivabradinum. The drug reduces the heart rate more than with medication without it.
Key words: percutaneous coronary intervention, myocardial reperfusion, stable angina, functional class of angina pectoris, quality of life.
Полный текст
Список литературы
1. Boden WE, O’Rourke RA, Teo KK et al. The evolving pattern of symftomatic coronary artery disease in the United and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol 2007.
2. Boden WE, O’Rourke RA, Teo KK et al. Desing and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperatie Studies Program no.424. Am Heart J 2006; 15 (6): 1173–9.
3. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial.RITA-2 trial participants. Lancet 1997; 350 (9076): 461–8.
4. Henderson RA, Pocock SJ, Clayton TC et al. Second Randomized Intervention Treatment of Angina (Rita-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J AM Coll Cardiol 2003; 42 (7): 1161–70.
5. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of singl-vessel coronary artery disease. Veterans AffairsA CME Investigators. N Engl J Med 1992; 326 (1): 10–6.
6. Weintraub WS, Barnett P, Chen S et al. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J 2006; 151 (6): 1180–5.
7. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
8. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation. 2012; 126 (25): e354–e471.
9. Godino C, Colombo A., Margonato A. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clin Drug Investig 2017; 37 (2): 105–20.
10. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
11. Steg P, Lopez-de-Sa E, Schiele F et al. VIVIFY (e Valuation of the Intra Venous If inhibitor ivabradine after ST segment elevation m Yocardial infarction) investigators. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur. Heart J Acute Cardiovasc Care 2013; 2 (3): 270–9.
12. Werdan K, Ebelt H, Nuding S et al. Ivabradine in combination with beta-blokers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther 2015; 32 (2): 120–37.
13. Fox K, Ford I, Steg PG et al; SIGNIFY Investigators. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 2015; 36 (46): 3291–6.
14. Perna GP, Battistoni I, Angelini L. Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study? G Ital Cardiol (Rome) 2015; 16 (3): 155–60.
15. Werdan K, Ebelt H, Nuding S et al; on behalf of the ADDITIONS Study Investigators. Ivabradine in combination with Metoprolol improves symftoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial. Cardiology 2016; 133: 83–90.
16. Biondi-Zoccai GG, Abbate A, Agostoni P et al; Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J 2003; 4 (4): 271–80.
17. Moreyra AE, Maniatis GA, Gu H et al; Myocardial Infarction Data Acquisition System (MIDAS 28) Study Group. Frequency of Stroke After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting (from an Eleven-Year Statewide Analysis). Am J Cardiol 2017; 119 (2): 197–202.
18. Chang M, Lee CW, Ahn JM et al. Outcomes of Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents in Older Adults. J Am Geriatr Soc 2017; 65 (3): 625–30.
19. Iqbal MB, Ilsley C, De Robertis F et al. Comparison of Outcomes of Coronary Artery Bypass Grafting Using Internal Mammary Graft Versus Percutaneous Coronary Intervention for Isolated Proximal Left Anterior Descending Narrowing. Am J Cardiol 2017; 119 (5): 719–26.
20. Taglimonte E, Cirillo T, Rigo F et al. Ivabradine and Bisoprolol on Doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther 2015; July 22.
21. Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008; 15 (5): 461–73.
22. Ruzyllo W, Tendera M, Ford I et al. Antianginal efficacy and safety of Ivabradine compared with amlodipine in patients in patients with stable effort angina pectoris: a 3-month randomized, double blind, multicentre, noninferiority trial. Drugs 2007; 67 (3): 393–405.
23. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I (f) current ingibitior ivabradine patients with chronic stable angina receiving beta-bloker therapyat 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
24. Skalidis EI, Hamilos MI, Chlouverakis G et al. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 2011; 215 (1): 160–5.
25. Mangiacapra F, Colaiori, Ricottini E et al. Heart Rate reduction by Ivabradine improvement of endothelial function in patients with coronary artery disease: the RIVENDEL study. Clin Res Cardiol 2017; 106 (1): 69–75.
26. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by Ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014; 100 (2): 160–6.
27. Shalnova SA, Oganov RG; on behalf of the participants registry clarify. Five Year Dynamics of Main Clinical Symftoms in Patients Wits Ischemic Heart Disease in Russia in Comparison With Other Countries (the CLARIFY Registry). Kardiologiia. 2017.
2. Boden WE, O’Rourke RA, Teo KK et al. Desing and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperatie Studies Program no.424. Am Heart J 2006; 15 (6): 1173–9.
3. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial.RITA-2 trial participants. Lancet 1997; 350 (9076): 461–8.
4. Henderson RA, Pocock SJ, Clayton TC et al. Second Randomized Intervention Treatment of Angina (Rita-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J AM Coll Cardiol 2003; 42 (7): 1161–70.
5. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of singl-vessel coronary artery disease. Veterans AffairsA CME Investigators. N Engl J Med 1992; 326 (1): 10–6.
6. Weintraub WS, Barnett P, Chen S et al. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J 2006; 151 (6): 1180–5.
7. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
8. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation. 2012; 126 (25): e354–e471.
9. Godino C, Colombo A., Margonato A. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clin Drug Investig 2017; 37 (2): 105–20.
10. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
11. Steg P, Lopez-de-Sa E, Schiele F et al. VIVIFY (e Valuation of the Intra Venous If inhibitor ivabradine after ST segment elevation m Yocardial infarction) investigators. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur. Heart J Acute Cardiovasc Care 2013; 2 (3): 270–9.
12. Werdan K, Ebelt H, Nuding S et al. Ivabradine in combination with beta-blokers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther 2015; 32 (2): 120–37.
13. Fox K, Ford I, Steg PG et al; SIGNIFY Investigators. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 2015; 36 (46): 3291–6.
14. Perna GP, Battistoni I, Angelini L. Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study? G Ital Cardiol (Rome) 2015; 16 (3): 155–60.
15. Werdan K, Ebelt H, Nuding S et al; on behalf of the ADDITIONS Study Investigators. Ivabradine in combination with Metoprolol improves symftoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial. Cardiology 2016; 133: 83–90.
16. Biondi-Zoccai GG, Abbate A, Agostoni P et al; Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J 2003; 4 (4): 271–80.
17. Moreyra AE, Maniatis GA, Gu H et al; Myocardial Infarction Data Acquisition System (MIDAS 28) Study Group. Frequency of Stroke After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting (from an Eleven-Year Statewide Analysis). Am J Cardiol 2017; 119 (2): 197–202.
18. Chang M, Lee CW, Ahn JM et al. Outcomes of Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents in Older Adults. J Am Geriatr Soc 2017; 65 (3): 625–30.
19. Iqbal MB, Ilsley C, De Robertis F et al. Comparison of Outcomes of Coronary Artery Bypass Grafting Using Internal Mammary Graft Versus Percutaneous Coronary Intervention for Isolated Proximal Left Anterior Descending Narrowing. Am J Cardiol 2017; 119 (5): 719–26.
20. Taglimonte E, Cirillo T, Rigo F et al. Ivabradine and Bisoprolol on Doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther 2015; July 22.
21. Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008; 15 (5): 461–73.
22. Ruzyllo W, Tendera M, Ford I et al. Antianginal efficacy and safety of Ivabradine compared with amlodipine in patients in patients with stable effort angina pectoris: a 3-month randomized, double blind, multicentre, noninferiority trial. Drugs 2007; 67 (3): 393–405.
23. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I (f) current ingibitior ivabradine patients with chronic stable angina receiving beta-bloker therapyat 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
24. Skalidis EI, Hamilos MI, Chlouverakis G et al. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 2011; 215 (1): 160–5.
25. Mangiacapra F, Colaiori, Ricottini E et al. Heart Rate reduction by Ivabradine improvement of endothelial function in patients with coronary artery disease: the RIVENDEL study. Clin Res Cardiol 2017; 106 (1): 69–75.
26. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by Ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014; 100 (2): 160–6.
27. Shalnova SA, Oganov RG; on behalf of the participants registry clarify. Five Year Dynamics of Main Clinical Symftoms in Patients Wits Ischemic Heart Disease in Russia in Comparison With Other Countries (the CLARIFY Registry). Kardiologiia. 2017.
________________________________________________
1. Boden WE, O’Rourke RA, Teo KK et al. The evolving pattern of symftomatic coronary artery disease in the United and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol 2007.
2. Boden WE, O’Rourke RA, Teo KK et al. Desing and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperatie Studies Program no.424. Am Heart J 2006; 15 (6): 1173–9.
3. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial.RITA-2 trial participants. Lancet 1997; 350 (9076): 461–8.
4. Henderson RA, Pocock SJ, Clayton TC et al. Second Randomized Intervention Treatment of Angina (Rita-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J AM Coll Cardiol 2003; 42 (7): 1161–70.
5. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of singl-vessel coronary artery disease. Veterans AffairsA CME Investigators. N Engl J Med 1992; 326 (1): 10–6.
6. Weintraub WS, Barnett P, Chen S et al. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J 2006; 151 (6): 1180–5.
7. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
8. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation. 2012; 126 (25): e354–e471.
9. Godino C, Colombo A., Margonato A. Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clin Drug Investig 2017; 37 (2): 105–20.
10. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
11. Steg P, Lopez-de-Sa E, Schiele F et al. VIVIFY (e Valuation of the Intra Venous If inhibitor ivabradine after ST segment elevation m Yocardial infarction) investigators. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur. Heart J Acute Cardiovasc Care 2013; 2 (3): 270–9.
12. Werdan K, Ebelt H, Nuding S et al. Ivabradine in combination with beta-blokers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther 2015; 32 (2): 120–37.
13. Fox K, Ford I, Steg PG et al; SIGNIFY Investigators. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 2015; 36 (46): 3291–6.
14. Perna GP, Battistoni I, Angelini L. Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study? G Ital Cardiol (Rome) 2015; 16 (3): 155–60.
15. Werdan K, Ebelt H, Nuding S et al; on behalf of the ADDITIONS Study Investigators. Ivabradine in combination with Metoprolol improves symftoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS trial. Cardiology 2016; 133: 83–90.
16. Biondi-Zoccai GG, Abbate A, Agostoni P et al; Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J 2003; 4 (4): 271–80.
17. Moreyra AE, Maniatis GA, Gu H et al; Myocardial Infarction Data Acquisition System (MIDAS 28) Study Group. Frequency of Stroke After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting (from an Eleven-Year Statewide Analysis). Am J Cardiol 2017; 119 (2): 197–202.
18. Chang M, Lee CW, Ahn JM et al. Outcomes of Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents in Older Adults. J Am Geriatr Soc 2017; 65 (3): 625–30.
19. Iqbal MB, Ilsley C, De Robertis F et al. Comparison of Outcomes of Coronary Artery Bypass Grafting Using Internal Mammary Graft Versus Percutaneous Coronary Intervention for Isolated Proximal Left Anterior Descending Narrowing. Am J Cardiol 2017; 119 (5): 719–26.
20. Taglimonte E, Cirillo T, Rigo F et al. Ivabradine and Bisoprolol on Doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther 2015; July 22.
21. Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008; 15 (5): 461–73.
22. Ruzyllo W, Tendera M, Ford I et al. Antianginal efficacy and safety of Ivabradine compared with amlodipine in patients in patients with stable effort angina pectoris: a 3-month randomized, double blind, multicentre, noninferiority trial. Drugs 2007; 67 (3): 393–405.
23. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I (f) current ingibitior ivabradine patients with chronic stable angina receiving beta-bloker therapyat 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
24. Skalidis EI, Hamilos MI, Chlouverakis G et al. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 2011; 215 (1): 160–5.
25. Mangiacapra F, Colaiori, Ricottini E et al. Heart Rate reduction by Ivabradine improvement of endothelial function in patients with coronary artery disease: the RIVENDEL study. Clin Res Cardiol 2017; 106 (1): 69–75.
26. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by Ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart 2014; 100 (2): 160–6.
27. Shalnova SA, Oganov RG; on behalf of the participants registry clarify. Five Year Dynamics of Main Clinical Symftoms in Patients Wits Ischemic Heart Disease in Russia in Comparison With Other Countries (the CLARIFY Registry). Kardiologiia. 2017.
Авторы
Д.М.Аронов, М.Г.Бубнова*
ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*mbubnova@gnicpm.ru
ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
*mbubnova@gnicpm.ru
________________________________________________
D.M.Aronov, M.G.Bubnova*
National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
*mbubnova@gnicpm.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.